American Clinical Research Services, a clinical research company formed by Latticework Capital Management, has bought Elixia, a clinical research network with operations spanning Florida, Massachusetts, Michigan and Missouri.
Founded in 2019, Elixia is a clinical trial site network with a particular focus on nephrology. Now, Elixia has carved a niche in tackling clinical challenges across nephrology, neuroscience and infectious diseases, with a notable focus on its 40 bed Phase I unit in Tampa, Fla., focused on renal and hepatically impaired patients.
“The integration of Elixia not only broadens our capabilities in nephrology but also enhances our collective expertise in neuroscience and allows us to multiply our sites capable of conducting complex metabolic indications,” comments Dustin Owen, CEO of ACRS. “Elixia’s presence in multiple states enhances our ability to access a diverse range of participants across the nation, beyond our current footprint of Southern California and Texas, enriching the breadth and depth of our research endeavors.”